- Inspira Technologies reported its **first commercial revenue** of **$289 thousand** for the six months ended June 30, 2025, alongside a **net loss of $6,398 thousand** for the same period.  **[1837493_0001213900-25-094366_ea025460401ex99-2_inspira.htm:0]** **[1837493_0001213900-25-094366_ea025460401ex99-1_inspira.htm:1]** **[1837493_0001213900-25-094366_ea025460401ex99-3_inspira.htm:4]** **[1837493_0001213900-25-094366_ea025460401ex99-3_inspira.htm:5]** 
- The company secured **$49.5 million in binding purchase orders** for its INSPIRA™ ART100 system in July and August 2025, with revenue recognition expected in **2026**, and is targeting an annual revenue run rate of at least **$70 million** in 2026.  **[1837493_0001213900-25-094366_ea025460401ex99-1_inspira.htm:0]** 
- Key operational milestones include achieving **97.35% accuracy** for its HYLA blood sensor in September 2025, successful first human treatment with the ART100 system in April 2025, and U.S. patent approval for the ART500 core technology in August 2025.  **[1837493_0001213900-25-094366_ea025460401ex99-1_inspira.htm:0]** 
- As of June 30, 2025, cash and cash equivalents were **$2,126 thousand**, and the financial statements indicate substantial doubt about the company's ability to continue as a going concern; however, the company subsequently raised **$4,701,062** through an at-the-market offering facility as of October 1, 2025.  **[1837493_0001213900-25-094366_ea025460401ex99-2_inspira.htm:0]** **[1837493_0001213900-25-094366_ea025460401ex99-1_inspira.htm:1]** **[1837493_0001213900-25-094366_ea025460401ex99-3_inspira.htm:1]** **[1837493_0001213900-25-094366_ea025460401ex99-1_inspira.htm:3]**

Inspira Technologies Reports First Half 2025 Financial Results and Business Update

- Inspira Technologies reported **revenues of $289,000** and a **net loss of $6,398,000** for the six months ended June 30, 2025, with cash and cash equivalents totaling **$2,126,000** as of that date.  **[1837493_a02300e65d0a4ec2a3699a54fcdf11ae_1]** **[1837493_a02300e65d0a4ec2a3699a54fcdf11ae_2]** 
- The company secured **$49.5 million in binding purchase orders** for its INSPIRA™ ART100 system in July and August 2025, with revenue recognition expected in 2026, and is targeting an annual revenue run rate of at least **$70 million in 2026**.  **[1837493_a02300e65d0a4ec2a3699a54fcdf11ae_0]** 
- Operational highlights include the successful first human treatment with the ART100 system in April 2025, its expanded use in lung transplantation procedures, and the HYLA™ blood sensor achieving **97.35% accuracy** in September 2025, advancing towards FDA submission.  **[1837493_a02300e65d0a4ec2a3699a54fcdf11ae_0]**

Inspira Technologies Reports First Half 2025 Financial Results and Provides 2026 Revenue Guidance

- **Inspira Technologies** announced that its **HYLA™ blood sensor** achieved **97.35% accuracy** in its latest performance testing phase.  **[1837493_0001213900-25-086686_ea025677301ex99-1_inspira.htm:0]** 
- These results represent a significant advancement and confirm the device's readiness for **U.S. Food and Drug Administration (FDA) submission for clearance**.  **[1837493_0001213900-25-086686_ea025677301ex99-1_inspira.htm:0]** 
- The **HYLA sensor** provides **continuous, non-invasive monitoring** of blood parameters and is being developed as a **standalone device** to penetrate the broader disposables market, leveraging a planned **razor-and-blade recurring revenue model**.  **[1837493_0001213900-25-086686_ea025677301ex99-1_inspira.htm:0]**

Inspira Technologies Announces HYLA Blood Sensor Accuracy Results and FDA Submission Progress

- Inspira Technologies OXY B.H.N. announced **pivotal results** for its HYLA blood sensor, achieving **97.35% accuracy** in its latest performance testing phase.  **[1837493_de711009afee4ad6835ef3dd115f713a_0]** 
- These results will support the **upcoming U.S. Food and Drug Administration (FDA) submission** for clearance and confirm the device's readiness for regulatory pathways in the U.S. and Europe.  **[1837493_de711009afee4ad6835ef3dd115f713a_0]** 
- The HYLA blood sensor provides **continuous, second-by-second, non-invasive monitoring** of key blood parameters, designed to enable real-time, life-saving decisions in critical care.  **[1837493_de711009afee4ad6835ef3dd115f713a_0]** **[1837493_de711009afee4ad6835ef3dd115f713a_1]** 
- While primarily designed for integration with Inspira's ART device line, the HYLA sensor is also being developed as a **standalone device** to penetrate the **broader disposables market** using a **razor-and-blade recurring revenue model**.  **[1837493_de711009afee4ad6835ef3dd115f713a_1]**

Inspira Technologies OXY B.H.N. (IINN)